卡瑞利珠单抗联合法米替尼对比卡瑞利珠单抗单药及研究者选择的化疗治疗复发或转移性宫颈癌:一项随机II期研究
该随机II期研究比较卡瑞利珠单抗联合法米替尼与卡瑞利珠单抗单药及研究者选择的化疗在复发或转移性宫颈癌中的疗效。主要终点为盲法独立中心评估的客观缓解率,联合组为41.0%,显著优于单药组的24.1%(差异16.9%,单侧P=0.0181)。联合组中位无进展生存期8.1个月,中位总生存期20.2个月,安全性可控。
要点
- 卡瑞利珠单抗联合法米替尼组盲法独立中心评估的客观缓解率为41.0%,显著高于卡瑞利珠单抗单药组的24.1%。
- 联合组中位无进展生存期为8.1个月,卡瑞利珠单抗组为4.1个月,化疗组为2.9个月。
- 联合组3级及以上治疗相关不良事件发生率为84.8%,卡瑞利珠单抗组为15.1%,化疗组为60.0%。
核心结论
- 在经治的复发或转移性宫颈癌患者中,卡瑞利珠单抗联合法米替尼提高了抗肿瘤活性,且安全性可控,可能提供一种新的治疗选择。
研究设计与样本
- 随机II期研究,将经治的复发或转移性宫颈癌患者随机分配至卡瑞利珠单抗联合法米替尼组、卡瑞利珠单抗组或研究者选择的化疗组。
- 卡瑞利珠单抗用法为200 mg静脉注射,每3周一次;法米替尼用法为20 mg口服,每日一次。
- 主要终点为意向治疗人群中盲法独立中心评估的客观缓解率,比较卡瑞利珠单抗联合法米替尼组与卡瑞利珠单抗组。
主要发现
- 截至2023年4月21日,卡瑞利珠单抗联合法米替尼组、卡瑞利珠单抗组和化疗组分别有105例、54例和35例患者接受治疗。
- 盲法独立中心评估的客观缓解率:联合组41.0%(95%CI 31.5至51.0)对比卡瑞利珠单抗组24.1%(95%CI 13.5至37.6),差异16.9%(95%CI 2.1至31.7),单侧P=0.0181。
- 研究者评估的客观缓解率:联合组42.9%(95%CI 33.2至52.9),卡瑞利珠单抗组22.2%(95%CI 12.0至35.6),化疗组14.3%(95%CI 4.8至30.3)。
- 研究者评估的中位无进展生存期:联合组8.1个月(95%CI 6.2至12.4),卡瑞利珠单抗组4.1个月(95%CI 2.1至5.1),化疗组2.9个月(95%CI 2.0至6.2)。
- 截至2023年10月19日,中位总生存期:联合组20.2个月(95%CI 15.3至未达到),卡瑞利珠单抗组14.9个月(95%CI 12.6至未达到),化疗组13.9个月(95%CI 7.4至20.0)。
临床怎么用
- 作者认为,卡瑞利珠单抗联合法米替尼在经治的复发或转移性宫颈癌中提高了抗肿瘤活性且安全性可控,可能提供一种新的治疗选择。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To compare camrelizumab (an anti-PD-1 monoclonal antibody) plus famitinib (a multitarget receptor tyrosine kinase inhibitor) versus camrelizumab and chemotherapy in recurrent or metastatic cervical cancer (R/M CC). METHODS: Patients with pretreated R/M CC were randomly assigned to receive camrelizumab (200 mg intravenously once every 3 weeks) plus famitinib (20 mg orally once daily), camrelizumab, or investigator's choice of chemotherapy. The primary end point was comparison of objective response rate (ORR) per blinded independent central review (BICR) for camrelizumab-famitinib versus camrelizumab in the intention-to-treat population. RESULTS: Overall, 105, 54, and 35 patients received camrelizumab-famitinib, camrelizumab, and chemotherapy, respectively. As of April 21, 2023, ORR per BICR was significantly improved with camrelizumab-famitinib compared with camrelizumab (41.0% [95% CI, 31.5 to 51.0] v 24.1% [95% CI, 13.5 to 37.6]; difference, 16.9% [95% CI, 2.1 to 31.7]; one-sided P = .0181). Per investigator, ORR with camrelizumab-famitinib was 42.9% (95% CI, 33.2 to 52.9), notably higher than 22.2% (95% CI, 12.0 to 35.6) with camrelizumab and 14.3% (95% CI, 4.8 to 30.3) with chemotherapy. Median progression-free survival per investigator was prolonged with camrelizumab-famitinib than camrelizumab and chemotherapy (8.1 months [95% CI, 6.2 to 12.4] vs 4.1 months [95% CI, 2.1 to 5.1] and 2.9 months [95% CI, 2.0 to 6.2]). Median overall survival with camrelizumab-famitinib, camrelizumab, and chemotherapy, as of October 19, 2023, was 20.2 months (95% CI, 15.3 to not reached [NR]), 14.9 months (95% CI, 12.6 to NR), and 13.9 months (95% CI, 7.4 to 20.0), respectively. Eighty-nine (84.8%), eight (15.1%), and 18 (60.0%) patients who received camrelizumab-famitinib, camrelizumab, and chemotherapy, respectively, experienced grade ≥3 treatment-related adverse events. CONCLUSION: Camrelizumab plus famitinib improved antitumor activity while exhibiting a manageable safety profile in patients with pretreated R/M CC, potentially offering a novel treatment option.
引用
- Xia L, Zhang K, Tang Y, et al. Camrelizumab Plus Famitinib versus Camrelizumab Alone and Investigator's Choice of Chemotherapy in Recurrent or Metastatic Cervical Cancer: A Randomized, Phase II Study. J Clin Oncol. 2025. PMID: 40561369. doi:10.1200/JCO-24-02495
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。